Lacerol Retard

Diltiazem Hydrochloride, the active ingredient in Lacerol Retard, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure, relieve chest pain from angina, and treat certain cardiac rhythm disturbances in adult patients.

GNH USA supplies Lacerol Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements across multiple regions.

Diltiazem is a calcium channel blocker used in cardiovascular disease management.

Hypertension: reduces systemic vascular resistance, helping to lower elevated blood pressure and improve long‑term control. Angina pectoris: enhances coronary blood flow while decreasing myocardial oxygen demand, thereby relieving chest pain episodes. Cardiac arrhythmias: slows atrioventricular conduction and can help control certain supraventricular tachyarrhythmias, improving rhythm stability.

Diltiazem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: light‑headedness, especially on standing.

Serious or Rare Side Effects: - Severe bradycardia: markedly reduced heart rate requiring medical attention. - Atrioventricular block: impaired conduction that may necessitate pacing. - Hypotension: significant drop in blood pressure leading to fainting or shock.

When prescribing Diltiazem, clinicians should observe several safety considerations to minimize risk. - Monitor blood pressure: check regularly to ensure therapeutic reduction without excessive hypotension. - Assess cardiac function: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Use caution in hepatic impairment: dose adjustment may be needed due to metabolism. - Avoid in severe heart failure: risk of worsening cardiac output. - Review concomitant medications: consider interactions that may potentiate bradycardia or hypotension. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Diltiazem interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Beta‑blockers: combined use can cause profound bradycardia and AV block. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase diltiazem plasma concentrations, raising toxicity risk. - Digoxin: elevated levels may lead to digoxin toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce diltiazem effectiveness. - Diuretics: additive hypotensive effect, monitor blood pressure. - NSAIDs: may blunt antihypertensive response, require BP monitoring.